Jupiter, FL – According to filings with the U.S. Securities and Exchange Commission, Expansion Therapeutics is raising $80,053,360.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Renato Skerlj played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Expansion Therapeutics
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in Jupiter, Florida.

To learn more about Expansion Therapeutics, visit http://www.expansionrx.com/

Contact:
Renato Skerlj, Chief Executive Officer
561-898-1515
rskerlj@expansionrx.com
https://www.linkedin.com/in/renato-skerlj-a1321ab/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved